The deposition of Ab amyloid in the walls of cortical and leptomeningeal blood vessels characterizes cerebral amyloid angiopathy (CAA). 1 Clinical presentation of CAA ranges from transient neurologic events to cognitive decline to symptomatic intracerebral hemorrhage (ICH). Radiologically, CAA can present with structural brain lesions (e.g., microbleeds, white matter hyperintensities, or microinfarcts). Imaging evaluation can demonstrate alterations of vascular physiology or direct visualization of the deposits with amyloid radioligands. 2 More recently, cortical superficial siderosis (CSS) has emerged as an imaging marker of CAA pathophysiology, with a characteristic predilection for the cerebral convexities, seen as a linear residue of blood products in the superficial layers of the cerebral cortex or in the subarachnoid spaces on T2* or gradientecho MRI. 3 An analysis of 1,062 patients (mean age 69.6 years) from the population-based Rotterdam Scan Study found that 0.7% of individuals with cerebral microbleeds in lobar locations also had CSS. 4 In another cohort, those with memory difficulties had higher prevalence of CSS as compared to those with no cognitive impairment or dementia. 5 Due to the considerable overlap between CAA and cognitive impairment, several investigators have questioned the development of CAA in the setting of an ongoing neurodegenerative process. Many researchers now propose a common therapeutic approach for patients with Alzheimer dementia and CAA due to common mechanisms of Ab accumulation in both diseases. 6 Alzheimer disease and CAA share putative genetic factors, such as the APOE genotype in both diseases. 7, 8 The e variants within the APOE gene are an important genetic risk factor for lobar spontaneous ICH (sICH). 7, 8 More recently, Shoamanesh et al. 9 described a close relationship between the presence of CSS and the APOE e2 genotype. The presence of one or more copies of the e4 allele is a potent risk factor for the occurrence of Alzheimer dementia. These intriguing results raise several possibilities. The greater prevalence of disseminated CSS in patients with hemorrhagic CAA is consistent with previous results and fits the theory that CSS occurs due to leaking of blood from involved cortical and leptomeningeal vessels. 1 The association of distinct APOE signatures with the 2 groups lends credence to a genetic basis for different phenotypic presentations of CAA. Patients who develop hemorrhagic CAA may prove distinct from those with nonhemorrhagic CAA, with different APOE genotypes invoking disparate pathways for disease occurrence. The study has several important clinical implications for diagnosis and therapeutic treatment of CAA. It is plausible that early genetic testing of patients with CAA may help predict risk for cognitive impairment or ICH. Additionally, practitioners could tailor antiplatelet and anticoagulant therapy depending on the risk for ICH and consider novel immunomodulatory therapy for those with cognitive impairment or with an APOE e4 genotype.
The strengths of the study are the relatively large sample size of patients with pathologically proven CAA and a systematic approach to characterization of imaging results. However, potential biases in study design must be considered when interpreting these results. The authors concede the possibility of selection bias due to lack of genetic information on all patients. A sampling bias could have been introduced due to pathologic evaluation of the more clinically advanced patients. The authors acknowledge that the differences in clinical presentation may arise from the longer duration of disease in patients with nonhemorrhagic CAA or the e4 genotype. Further investigations into mechanisms that drive these differences are warranted and need to account for these issues.
Practitioners should direct their attention towards appropriately diagnosing CAA and identifying imaging markers that increase risk for hemorrhage. One potential avenue would be to consider formal neuropsychological testing in patients with nonhemorrhagic CAA as well as APOE genotype testing in those with signs of cognitive impairment. The community awaits validation of these results in even larger CAA cohorts.
